Top news of the week: 22.09.2020.
Biotechnology, Federal government of the United States, Good clinical practice, Management occupations, Clinical trial, Oncology
Startups
RT @LifeSciVC: Evolution Of The Biotech IPO Markets From Busted To Booming.
In 2000s, many IPOs priced way below their expected IPO range. Today, it's all about upsizing & above the range.
Why? Significant structural changes in the markets and in the IPO process.
https://t.co/uOiCn5Rr7G
OpenEvolution Of The Biotech IPO Markets From Busted To Booming
In the excitement of today’s biotech IPO market, and the bullish period since 2013, it’s almost hard to remember how painful the equity capital markets were back in the day. When I began my ...
RT @BioStocks: $LEGN CEO is presently under residential surveillance by PRC law enforcement.
Appoints interim CEO
https://t.co/HlVCe4s6hR
OpenLegend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEO
Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for ...
Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field https://t.co/yOi58cMWRW https://t.co/ZR4CAmERuk
OpenRoche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral NLRP3 ...
Very happy that Moderna is sharing their Phase 3 COVID-19 vaccine protocol. Let this be an example for other Warp Speed manufacturers. Excellent scientific transparency. https://t.co/cRClfbPTE9
OpenModerna, in bid for transparency, discloses detailed plan of coronavirus vaccine trial
The biotech, among the furthest along in coronavirus vaccine development, is the first developer to share the so-called study protocol of its Phase 3 trial.
Moderna's CEO told us we should know if the biotech's coronavirus vaccine works in November https://t.co/H0nwBOHKbO
OpenModerna's CEO told us we should know if the biotech's coronavirus vaccine works in November
The biotech slowed down its vaccine trials to recruit more diverse volunteers, particularly from the Black community.
RT @markpothier: #Moderna says it expects to know in November whether COVID-19 #vaccine works. https://t.co/uLMy74uW3I
OpenModerna CEO: Company expects to know in November whether COVID-19 vaccine works
Stephane Bancel says the Cambridge biotech could deliver 100 million doses to the federal government early next year.
Chutes & Ladders—Olema Oncology brings on AstraZeneca vet Bohen as CEO https://t.co/MBW9mASFYt https://t.co/w9tsO5xJwb
OpenChutes & Ladders—Olema Oncology brings on AstraZeneca vet Bohen as CEO
AZ veteran Bohen joins Olema Oncology as CEO; Cygnal Therapeutics taps Wagner as CMO; Dawkins one of two R&D execs hired at Forma.
. Lava is moving several lead Vγ9Vδ2 T-cell engagers toward the clinic. Buoyed by the funding, Lava expects to start proof-of-concept trials of the therapies next year https://t.co/j1yWLVa10a
OpenNovo, Sanofi VC units lead Lava's $83M series C to fund gamma delta T-cell trials
Lava Therapeutics has raised $83 million to advance its portfolio of bispecific gamma delta T-cell engagers. The series C positions Lava to begin assessing the drugs in proof-of-concept ...